AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23164205 — intervention group
Group type: COMPARATOR
Intervention: Bacteriostatic normal saline
Number of subjects: 376
Study 20180607 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 32
Study 20180607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17936590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90
Study 17936590 — intervention group
Group type: COMPARATOR
Intervention: Befriending (BF)
Number of subjects: 90
Study 16075327 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl
Number of subjects: 40
Study 16075327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11752037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) 1 g/d
Number of subjects: 7
Study 11752037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10432909 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse assessment protocol
Number of subjects: 540
Study 10432909 — intervention group
Group type: COMPARATOR
Intervention: No abuse assessment protocol (control)
Number of subjects: 540
Study 7487504 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical conditioning (PC) started 15 days after MRS, with a training intensity up to five metabolic units, three times a week for 1 hour and 15 minutes.
Number of subjects: 22
Study 7487504 — intervention group
Group type: COMPARATOR
Intervention: Physical conditioning (PC) started 3 months after MRS, with a training intensity of about 70% of the maximum heart rate reserve, three times a week for 1 hour.
Number of subjects: 22
Study 2275253 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion diet
Number of subjects: 26
Study 2275253 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (low in refined carbohydrates and rich in fiber)
Number of subjects: 26
Study 2275253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary groups (Exclusion diet and Standard diet)
Number of subjects: 26
Study 6766274 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin, 6 gm by mouth every 24 hours
Number of subjects: 30
Study 6766274 — intervention group
Group type: COMPARATOR
Intervention: Aqueous penicillin G, 30 million units and gentamicin, 180 to 240 mg intravenously every 24 hours
Number of subjects: 30
Study 30621764 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (PP100‐01) co-administered with a 12-h NAC regimen
Number of subjects: 24
Study 30621764 — intervention group
Group type: COMPARATOR
Intervention: NAC treatment alone
Number of subjects: 24
Study 28738857 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) - invitation letter to male partner offering HIV testing
Number of subjects: 21
Study 28738857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits (one of five intervention arms)
Number of subjects: 21
Study 28738857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits with financial incentive (fixed or lottery amount)
Number of subjects: 21
Study 28738857 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-test kits with phone call reminders
Number of subjects: 21
Study 25994445 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral intervention promoting home-based unsupervised exercise
Number of subjects: 194
Study 25994445 — intervention group
Group type: COMPARATOR
Intervention: Control group attending weekly lectures
Number of subjects: 194
Study 24099350 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishe Pill (3.75 g twice a day for 28 days)
Number of subjects: 240
Study 24099350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.75 g twice a day for 28 days)
Number of subjects: 240
Study 21216583 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium chloride 400 μg
Number of subjects: 25
Study 20361676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron sorbitol (IS)
Number of subjects: 146
Study 20361676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium iron edetate (SIE)
Number of subjects: 146
Study 20361676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron polymaltose complex (IPC)
Number of subjects: 146
Study 17899047 — intervention group
Group type: EXPERIMENTAL
Intervention: IDAS II
Number of subjects: 24
Study 17899047 — intervention group
Group type: COMPARATOR
Intervention: MEMS
Number of subjects: 24
Study 17899047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 24
Study 15117055 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 10 mg (Group 1)
Number of subjects: 90
Study 15117055 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 10 mg/antioxidants/vitamins and minerals broad spectrum supplementation formula (Group 2)
Number of subjects: 90
Study 15117055 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (Group 3)
Number of subjects: 90
Study 11605923 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin solution
Number of subjects: 20
Study 11605923 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch solution
Number of subjects: 20
Study 9210677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg once a day for 10 days
Number of subjects: 1798
Study 9210677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg twice a day for 10 days
Number of subjects: 1798
Study 9210677 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 500 mg three times a day for 10 days
Number of subjects: 1798
Study 9210677 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (both dosages)
Number of subjects: 1798
Study 9210677 — intervention group
Group type: COMPARATOR
Intervention: Cefdinir and Amoxicillin-clavulanate (both groups)
Number of subjects: 1798
Study 7683742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cotrimoxazole
Number of subjects: 105
Study 7683742 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 105
Study 3302923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (39 mothers) received anticipatory guidance with discussions of developmental stages.
Number of subjects: 83
Study 3302923 — intervention group
Group type: COMPARATOR
Intervention: Control group (44 mothers) received standard anticipatory guidance without developmental discussions.
Number of subjects: 83
Study 2625689 — intervention group
Group type: EXPERIMENTAL
Intervention: BID salsalate (3500 mg/day)
Number of subjects: 40
Study 2625689 — intervention group
Group type: COMPARATOR
Intervention: BID naproxen (750 mg/day)
Number of subjects: 40
Study 30936633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometer cycling (60 minutes per session, 3 times per week for 8 weeks)
Number of subjects: 20
Study 30936633 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (same duration as experimental group)
Number of subjects: 20
Study 27929693 — intervention group
Group type: EXPERIMENTAL
Intervention: New external fixators
Number of subjects: 95
Study 27929693 — intervention group
Group type: COMPARATOR
Intervention: Recycled external fixators
Number of subjects: 95
Study 26051796 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including simplifying materials and tailoring recruitment activities to specific communities' needs.
Number of subjects: 96
Study 23548990 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually targeted physical activity counseling and supervised strength and balance training once a week.
Number of subjects: 559
Study 23548990 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 559
Study 21739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech rehabilitation plus acupuncture (observation group 1)
Number of subjects: 120
Study 21739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech rehabilitation plus acupuncture combined with psychotherapy (observation group 2)
Number of subjects: 120
Study 21739683 — intervention group
Group type: COMPARATOR
Intervention: Speech rehabilitation (control group)
Number of subjects: 120
Study 19453794 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 711
Study 19453794 — intervention group
Group type: COMPARATOR
Intervention: Paused therapy (control)
Number of subjects: 711
Study 16923636 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 5 daily sessions)
Number of subjects: 10
Study 16923636 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 10
Study 15224788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide lotion 10%
Number of subjects: 0
Study 15224788 — intervention group
Group type: COMPARATOR
Intervention: Selenium sulfide lotion 2.5%
Number of subjects: 0
Study 11513054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 90
Study 11513054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 50 mg
Number of subjects: 90
Study 11513054 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 90
Study 9267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 90 mg t.i.d.
Number of subjects: 300
Study 9267856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 9267856 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 30 mg t.i.d.
Number of subjects: 300
Study 8289404 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN/GLN
Number of subjects: 29
Study 8289404 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 29
Study 2882082 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal alcohol drinking
Number of subjects: 44
Study 2882082 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol beer
Number of subjects: 44
Study 31464558 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster CYD‐TDV dose (Group 1)
Number of subjects: 118
Study 31464558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 2)
Number of subjects: 118
Study 31241683 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) applied over the left dorsolateral prefrontal cortex and left temporoparietal junction for 10 sessions over 5 consecutive days.
Number of subjects: 100
Study 31241683 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 100
Study 28290731 — intervention group
Group type: EXPERIMENTAL
Intervention: LBAL (biosimilar adalimumab)
Number of subjects: 116
Study 28290731 — intervention group
Group type: COMPARATOR
Intervention: Humira (originator adalimumab)
Number of subjects: 116
Study 25052130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g)
Number of subjects: 299
Study 25052130 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml isotonic sodium chloride)
Number of subjects: 299
Study 24330903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose unilateral brief pulse ECT (1.0 millisecond)
Number of subjects: 116
Study 24330903 — intervention group
Group type: COMPARATOR
Intervention: High-dose unilateral ultrabrief pulse ECT (0.3-0.4 millisecond)
Number of subjects: 116
Study 21394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (6-MP + MTX) in SRG
Number of subjects: 429
Study 21394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (rotated drug pairs) in SRG
Number of subjects: 429
Study 21394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (rotated drug pairs) in IRG
Number of subjects: 429
Study 21394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C (6-MP + MTX + VCR + dexamethasone) in IRG
Number of subjects: 429
Study 21394895 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall for all patients
Number of subjects: 429
Study 18337331 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 100
Study 18337331 — intervention group
Group type: COMPARATOR
Intervention: Triclabendazole
Number of subjects: 100
Study 16966983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychosocial follow‐up services, family or group therapy, and assisted with substance abuse treatment (n = 56)
Number of subjects: 100
Study 16966983 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment and follow‐through in accordance with standard parole or probation procedures (n = 44)
Number of subjects: 100
Study 15615423 — intervention group
Group type: EXPERIMENTAL
Intervention: Manshuailing oral liquid (CH group)
Number of subjects: 90
Study 15615423 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (RT group)
Number of subjects: 90
Study 10356669 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP/P-1 (25 micrograms vasoactive intestinal polypeptide combined with 1.0 mg phentolamine mesylate)
Number of subjects: 304
Study 10356669 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP/P-2 (25 micrograms vasoactive intestinal polypeptide combined with 2.0 mg phentolamine mesylate)
Number of subjects: 304
Study 10356669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 10356669 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP/P-1
Number of subjects: 304
Study 7490372 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 17
Study 7490372 — intervention group
Group type: COMPARATOR
Intervention: UVA as placebo
Number of subjects: 17
Study 1659174 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin‐C/ifosfamide (A)
Number of subjects: 192
Study 1659174 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine (B)
Number of subjects: 192
Study 1659174 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin/etoposide (C)
Number of subjects: 192
Study 7138754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally every 6 h for a total of five doses prior to diazepam 10 mg
Number of subjects: 7
Study 7138754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29883190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingent Financial Incentives (PN+CM)
Number of subjects: 0
Study 29883190 — intervention group
Group type: COMPARATOR
Intervention: Patient Navigation without Contingent Financial Incentives (PN)
Number of subjects: 0
Study 29883190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PN+CM and PN)
Number of subjects: 0
Study 27160892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90)
Number of subjects: 13199
Study 27160892 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg on day 1 followed by 100 mg daily for days 2 through 90)
Number of subjects: 13199
Study 27160892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13199
Study 27160892 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13199
Study 24346235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + laser photocoagulation (RL group, n=10)
Number of subjects: 22
Study 24346235 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab only (Control R group, n=12)
Number of subjects: 22
Study 22730539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) at 5 mg/m², repeated after 3 weeks
Number of subjects: 120
Study 22730539 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 120
Study 20383090 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (3 hours in a simulation laboratory)
Number of subjects: 0
Study 20383090 — intervention group
Group type: COMPARATOR
Intervention: Didactic training (3 hours of lectures/video and hands‐on demonstration)
Number of subjects: 0
Study 18520604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDMA (1.0 mg/kg)
Number of subjects: 17
Study 18520604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MDMA (1.6 mg/kg)
Number of subjects: 17
Study 18520604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17187741 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program (HE) for mothers
Number of subjects: 200
Study 17187741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 12483239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin‐bonded resin composite (Retroplast, RP)
Number of subjects: 134
Study 12483239 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (Chelon‐Silver, CS)
Number of subjects: 134
Study 9523420 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0
Study 9523420 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0
Study 7649973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 0
Study 7649973 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 7649973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2696505 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 2696505 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 20
Study 350215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 350215 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo response)
Number of subjects: 0
Study 31912605 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 80
Study 31912605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31375749 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (50g/300ml)
Number of subjects: 16
Study 31375749 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution with EB
Number of subjects: 16
Study 31375749 — intervention group
Group type: COMPARATOR
Intervention: Water with EB
Number of subjects: 16
Study 31375749 — intervention group
Group type: COMPARATOR
Intervention: Plain water
Number of subjects: 16
Study 31375749 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution without EB
Number of subjects: 16
Study 29042371 — intervention group
Group type: EXPERIMENTAL
Intervention: Collum Femoris Preserving short stem
Number of subjects: 150
Study 29042371 — intervention group
Group type: COMPARATOR
Intervention: Zweymuller Alloclassic conventional stem
Number of subjects: 150
Study 25664779 — intervention group
Group type: EXPERIMENTAL
Intervention: Counsel and support from district nurses based on empowerment
Number of subjects: 0
Study 25664779 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 23771193 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg single dose in postbariatric surgery group
Number of subjects: 10
Study 23771193 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical control group
Number of subjects: 10
Study 22384546 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule (NC)
Number of subjects: 104
Study 22384546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongguan Capsule
Number of subjects: 104
Study 22384546 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 104
Study 19184086 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia at 200 W
Number of subjects: 12
Study 19184086 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxia at 200 W
Number of subjects: 12
Study 19184086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia at 150 W
Number of subjects: 12
Study 16543519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation
Number of subjects: 95
Study 15673175 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective imposed by language (e.g., 'You are driving a car' or 'You are fueling a car')
Number of subjects: 0
Study 15673175 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions directed toward parts of the car (e.g., roof or wheels)
Number of subjects: 0
Study 11729034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (15 mg)
Number of subjects: 54
Study 11729034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9220521 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms/day
Number of subjects: 62
Study 9220521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 7838188 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory arrest
Number of subjects: 171
Study 7838188 — intervention group
Group type: COMPARATOR
Intervention: Low-flow bypass
Number of subjects: 171
Study 2203486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RO 42-5892 (100 micrograms/kg)
Number of subjects: 9
Study 2203486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RO 42-5892 (1000 micrograms/kg)
Number of subjects: 9
Study 2203486 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral RO 42-5892 (600 mg)
Number of subjects: 9
Study 359383 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone
Number of subjects: 40
Study 359383 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 40
Study 31958667 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared a lot treatment (another child shared 6 stickers)
Number of subjects: 2500
Study 31958667 — intervention group
Group type: COMPARATOR
Intervention: Shared a little treatment (another child shared 1 sticker)
Number of subjects: 2500
Study 30975923 — intervention group
Group type: EXPERIMENTAL
Intervention: Seribantumab + erlotinib
Number of subjects: 129
Study 30975923 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 129
Study 30975923 — intervention group
Group type: EXPERIMENTAL
Intervention: Seribantumab + erlotinib (in HRG positive patients)
Number of subjects: 129
Study 30975923 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone (in HRG negative patients)
Number of subjects: 129
Study 28118028 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) delivered to the tumour bed and regional lymph nodes up to 50.4 Gy (range, 45‐61 Gy)
Number of subjects: 59
Study 28118028 — intervention group
Group type: COMPARATOR
Intervention: Observation (no adjuvant treatment)
Number of subjects: 59